Paper
Journal of Generic Medicines (2004) 1, 259–265; doi:10.1057/palgrave.jgm.4940030
Are biopharmaceuticals immune to the generics threat?
Enrico T Polastro1 and Sonia Tulcinsky2
- 1Vice President and Industry Specialist, Arthur D. Little, Benelux sa/nv, Bd de la Woluwelaan 2, B-1150, Brussels, Belgium, Tel: +32 2 7617222, Fax: +32 2 7620758, Email: polastro.e@adlittle.com
- 2Consultant in the European pharmaceutical and fine chemicals practice of Arthur D. Little
Revised 5 January 2004.
Top of page
Abstract
Although patents on several key biopharmaceuticals expired some years ago, biogenerics have not yet reached the market in the Triad (Japan, North America and Western Europe)1 — a situation contrasting with other markets such as China, South-East Asia and Latin America, where biogenerics are a reality. This paper provides a broad overview of the ongoing developments in the biogenerics scene and discusses the issues and hurdles faced by prospective biogenerics developers in the Triad.
Keywords:
biogenerics, Triad, developments, patents
